RapaLink-1
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity[1][2].
Product Specifications
CAS Number
[1887095-82-0]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; mTOR
Type
Reference compound
Related Pathways
Autophagy; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rapalink-1.html
Purity
99.65
Solubility
DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL
Smiles
Molecular Formula
C91H138N12O24
Molecular Weight
1784.14
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MTOR
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items